Braveheart Bio (BRVE) analyst forecast and price target
Analyst forecast
Consensus of 5 analyst ratings
Based on 4 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Cantor Fitzgerald | Initiated Coverage | Overweight | $40.00 | Aug 31, 2026 |
| TD Cowen | Initiated Coverage | Buy | — | Aug 31, 2026 |
| Stifel | Initiated Coverage | Buy | $45.00 | Aug 31, 2026 |
| Goldman Sachs | Initiated Coverage | Buy | $48.00 | Aug 31, 2026 |
| Jefferies | Initiated Coverage | Buy | $48.00 | Aug 31, 2026 |
Frequently asked questions
What is the price target for BRVE stock?
The average 12-month analyst price target for Braveheart Bio (BRVE) is $45.25, with a high estimate of $48.00 and a low of $40.00, across 4 analysts.
Is BRVE a buy, sell, or hold?
Analysts covering Braveheart Bio currently average a Buy rating: 5 buy, 0 hold and 0 sell, from 5 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for BRVE?
The average price target of $45.25 implies 133.97% upside from the last price of $19.34.
What is the latest analyst rating on BRVE?
On Aug 31, 2026, Cantor Fitzgerald initiated coverage of Braveheart Bio at Overweight with a price target of $40.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.